Xeris Biopharma Holdings (XERS) Operating Expenses (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Operating Expenses for 7 consecutive years, with $86.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 29.63% year-over-year to $86.9 million; the trailing twelve-month figure through Jun 2026 stood at $298.8 million (up 16.8% YoY), and the FY2025 full-year result was $266.9 million, up 12.77% from the prior year.
• Operating Expenses grew to $86.9 million in Q2 2026 per XERS's latest filing, from $75.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $86.9 million in Q2 2026 and bottomed at $44.2 million in Q2 2022.
• Historically, Operating Expenses has averaged $59.2 million across 5 years, with a median of $55.6 million in 2024.
• The widest YoY moves for Operating Expenses: up 105.12% in 2022, down 30.68% in 2022.
• Over 5 years, Operating Expenses stood at $48.3 million in 2022, then climbed by 12.25% to $54.2 million in 2023, then gained by 7.72% to $58.4 million in 2024, then climbed by 18.17% to $69.0 million in 2025, then advanced by 25.92% to $86.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $86.9 million, $75.2 million, and $69.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.